Frances M Saccoccio1, Jennifer A Jenks2, Hannah L Itell2, Shuk Hang Li2, Madison Berry2, Justin Pollara3, Corey Casper4, Soren Gantt5, Sallie R Permar1,2. 1. Division of Pediatric Infectious Diseases, Duke University, Durham, North Carolina. 2. Duke Human Vaccine Institute, Duke University, Durham, North Carolina. 3. Department of Surgery, Duke University Medical Center, Duke University, Durham, North Carolina. 4. Infectious Disease Research Institute, Seattle, Washington. 5. BC Children's Hospital Research Institute, University of British Columbia, Vancouver, Canada.
Abstract
BACKGROUND: Development of a cytomegalovirus (CMV) vaccine is a high priority. However, the ability of antibodies to protect against CMV infection is not well characterized. Studies of maternal antibodies in infants offer the potential to identify humoral correlates of protection against postnatal acquisition. METHODS: This hypothesis-generating study analyzed 29 Ugandan mother-infant pairs that were followed weekly for CMV acquisition. Seventeen mothers and no infants were infected with human immunodeficiency virus (HIV). We evaluated the association between CMV-specific immunoglobulin G (IgG) responses in mothers at the time of delivery and their infants' CMV status at 6 months of age. We also assessed levels of CMV-specific IgG in infants at 6 weeks of age. CMV-specific IgG responses in the mother-infant pairs were then analyzed on the basis of perinatal HIV exposure. RESULTS: We found similar levels of multiple CMV glycoprotein-specific IgG binding specificities and functions in mothers and infants, irrespective of perinatal HIV exposure or infant CMV status at 6 months of age. However, the glycoprotein B-specific IgG titer, measured by 2 distinct assays, was higher in infants without CMV infection and was moderately associated with delayed CMV acquisition. CONCLUSIONS: These data suggest that high levels of glycoprotein B-specific IgG may contribute to the partial protection against postnatal CMV infection afforded by maternal antibodies, and they support the continued inclusion of glycoprotein B antigens in CMV vaccine candidates.
BACKGROUND: Development of a cytomegalovirus (CMV) vaccine is a high priority. However, the ability of antibodies to protect against CMV infection is not well characterized. Studies of maternal antibodies in infants offer the potential to identify humoral correlates of protection against postnatal acquisition. METHODS: This hypothesis-generating study analyzed 29 Ugandan mother-infant pairs that were followed weekly for CMV acquisition. Seventeen mothers and no infants were infected with human immunodeficiency virus (HIV). We evaluated the association between CMV-specific immunoglobulin G (IgG) responses in mothers at the time of delivery and their infants' CMV status at 6 months of age. We also assessed levels of CMV-specific IgG in infants at 6 weeks of age. CMV-specific IgG responses in the mother-infant pairs were then analyzed on the basis of perinatal HIV exposure. RESULTS: We found similar levels of multiple CMV glycoprotein-specific IgG binding specificities and functions in mothers and infants, irrespective of perinatal HIV exposure or infant CMV status at 6 months of age. However, the glycoprotein B-specific IgG titer, measured by 2 distinct assays, was higher in infants without CMV infection and was moderately associated with delayed CMV acquisition. CONCLUSIONS: These data suggest that high levels of glycoprotein B-specific IgG may contribute to the partial protection against postnatal CMV infection afforded by maternal antibodies, and they support the continued inclusion of glycoprotein B antigens in CMV vaccine candidates.
Authors: Robert F Pass; Changpin Zhang; Ashley Evans; Tina Simpson; William Andrews; Meei-Li Huang; Lawrence Corey; Janie Hill; Elizabeth Davis; Cynthia Flanigan; Gretchen Cloud Journal: N Engl J Med Date: 2009-03-19 Impact factor: 91.245
Authors: Brent J Ryckman; Barb L Rainish; Marie C Chase; Jamie A Borton; Jay A Nelson; Michael A Jarvis; David C Johnson Journal: J Virol Date: 2007-10-17 Impact factor: 5.103
Authors: Eleanor C Semmes; Itzayana G Miller; Courtney E Wimberly; Caroline T Phan; Jennifer A Jenks; Melissa J Harnois; Stella J Berendam; Helen Webster; Jillian H Hurst; Joanne Kurtzberg; Genevieve G Fouda; Kyle M Walsh; Sallie R Permar Journal: J Clin Invest Date: 2022-08-15 Impact factor: 19.456